Status:
COMPLETED
Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Chronic Kidney Disease
Renal Transplantation
Eligibility:
All Genders
18-18 years
Phase:
PHASE4
Brief Summary
Vitamin D is not seen anymore only as a phosphocalcic and bone hormone, but also as having an effect on global health (anti-infective, anti-inflammatory, anti-tumour roles and cardiovascular protectio...
Eligibility Criteria
Inclusion
- Age : between \[18 mo et 18 yo\[
- Patients seen in the paediatric nephrology service and having :
- Chronic kidney disease
- Renal transplant
- Stable nephrotic syndrome (i.e., normal protidemia at inclusion)
- Initial 25 OH vitamin D concentration \< 75nmol/l
- Patient agree to participate (if old enough to give his agreement) and written informed consent signed by parents
- Patients affiliated within the French universal healthcare system
Exclusion
- \- Contraindication to 100 000 IU Uvedose® treatment (according to the Summary of Product Characteristics: known hypersensitivity to vitamin D or hypercalcemia, hypercalciuria or nephrolithiasis).
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2017
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT02238418
Start Date
September 1 2014
End Date
October 1 2017
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de Référence des Maladies Rénales Rares - Hospices Civils de Lyon - Service de Néphrologie et Rhumatologie Pédiatriques - Hôpital Femme Mère Enfant
Bron, France, 69500